Sang, Y.B.; Yang, H.; Lee, W.S.; Lee, S.J.; Kim, S.-G.; Cheon, J.; Kang, B.; Kim, C.W.; Chon, H.J.; Kim, C.
High Serum Levels of IL-6 Predict Poor Responses in Patients Treated with Pembrolizumab plus Axitinib for Advanced Renal Cell Carcinoma. Cancers 2022, 14, 5985.
https://doi.org/10.3390/cancers14235985
AMA Style
Sang YB, Yang H, Lee WS, Lee SJ, Kim S-G, Cheon J, Kang B, Kim CW, Chon HJ, Kim C.
High Serum Levels of IL-6 Predict Poor Responses in Patients Treated with Pembrolizumab plus Axitinib for Advanced Renal Cell Carcinoma. Cancers. 2022; 14(23):5985.
https://doi.org/10.3390/cancers14235985
Chicago/Turabian Style
Sang, Yun Beom, Hannah Yang, Won Suk Lee, Seung Joon Lee, Seul-Gi Kim, Jaekyung Cheon, Beodeul Kang, Chang Woo Kim, Hong Jae Chon, and Chan Kim.
2022. "High Serum Levels of IL-6 Predict Poor Responses in Patients Treated with Pembrolizumab plus Axitinib for Advanced Renal Cell Carcinoma" Cancers 14, no. 23: 5985.
https://doi.org/10.3390/cancers14235985
APA Style
Sang, Y. B., Yang, H., Lee, W. S., Lee, S. J., Kim, S.-G., Cheon, J., Kang, B., Kim, C. W., Chon, H. J., & Kim, C.
(2022). High Serum Levels of IL-6 Predict Poor Responses in Patients Treated with Pembrolizumab plus Axitinib for Advanced Renal Cell Carcinoma. Cancers, 14(23), 5985.
https://doi.org/10.3390/cancers14235985